The demand for high-end pharmaceutical equipment is growing stronger, and the market share is expected to continue to increase

In recent years, with the vigorous development of the biomedical industry, the demand for pharmaceutical equipment has become increasingly strong
.
The data shows that the domestic pharmaceutical equipment, process system and service market scale in 2019 is about 90 billion yuan, and it is expected that by 2024, this market will reach 174 billion yuan
.
At present, there are more than 5,000 companies in China's pharmaceutical market.
Affected by policy factors such as centralized procurement and consistency evaluation, the number of pharmaceutical companies will gradually decrease in the future, and the industry concentration will continue to increase
.
In this context, a number of small and medium-sized enterprises will be eliminated, and enterprises with strong comprehensive strength will remain, increasing industrial upgrading and innovation and international layout, and the corresponding high-end pharmaceutical equipment is also expected to usher in further growth
.
Guosen Securities once pointed out in a report that the compound growth rate of China's high-end pharmaceutical equipment market from 2015 to 2019 was 18.
9%, and from 2019 to 2024, the compound growth rate is expected to be 17.
1%, compared with 12.
7% in the low-end market in the same period.
, 12.
4% compound growth rate, the growth rate is significantly faster
.
From the perspective of the market share of high-end pharmaceutical equipment, high-end equipment has increased from 24% in 2015 to 28% in 2019
.
As China's production supervision of the biomedical industry continues to be strengthened, pharmaceutical equipment is also required to be further standardized.
It is expected that the market share of high-end pharmaceutical equipment will gradually increase, and it is expected to further increase to 32% in 2024
.
From the above data, the market share of domestic high-end pharmaceutical equipment is continuing to increase, which also means that high-end equipment companies are ushering in opportunities and are expected to accelerate the pace of import substitution in the future
.
The Jiufang Financial Research Institute also stated in a research report previously that after ten years of industrial chain development, domestic pharmaceutical equipment companies have gradually become a subdivision of China’s high-end manufacturing, domestic substitution has accelerated, export overseas business has grown rapidly, and the industry has gradually Long-term growth is ushered in the fading of the cycle attribute
.
At present, the high-end pharmaceutical equipment market has become a new force for many pharmaceutical machinery companies.

.
For example, at the 87th API China, a reactor manufacturer stated in an interview with Pharmanet that the company is not taking the quantitative route and is moving towards the mid-to-high-end direction.
This exhibition also hopes to be able to get in touch with more mid-to-high-end products.
Customers, while expanding the market, provide our customers with more high-quality products.
At the same time, the company will continue to expand the mid-to-high-end market in the future to meet customer needs.
Some bio-pharmaceutical equipment manufacturers say that although import manufacturers are currently engaged in mid-to-high-end biopharmaceuticals The equipment market still occupies the right to speak, but the high-end field has become the main direction of domestic enterprises.
In the future, with the acceleration of intelligence, automation and technological progress, domestic equipment is expected to further realize the reversal of the market position of imported pharmaceutical equipment
.
A group of pharmaceutical machinery companies that have deployed high-end pharmaceutical equipment in the field have made breakthroughs in new products and new technologies
.
For example, Canaan Technology recently announced that the company's wet granulation technology has a breakthrough iteration: using a specially developed and designed new granulation structure to achieve a primary yield of more than 97% of 10-80 mesh particles and more than 92% of 10-40 meshes.
The production capacity can reach 700kg/h, and the obtained particle size distribution is more concentrated
.
According to its experimental results, the iterative new wet granulation technology can significantly improve the primary yield and production efficiency, and provide a new technological solution for the wet granulation process
.
There are also pharmaceutical companies that conform to the new market demand and create high-end bio-extraction equipment that is more energy-efficient and cost-reducing, which can save energy by 0.
3-0.
5 times, and can reduce solvents by 0.
5-1 times according to different drugs, and increase feed volume by 30%-60% , Make the paste rate increase by more than 10%
.
It is worth mentioning that the change in the mid-to-high-end market pattern cannot be successful overnight
.
While setting goals, domestic pharmaceutical equipment companies also need to increase energy, capital, and hard work in R&D investment, precision technology and basic science, and gradually accumulate rich experience to create innovative and high-tech Only high-end equipment can meet the needs of the modern pharmaceutical industry, especially the biopharmaceutical industry
.